A 2026 Australian interview study involving 27 adults with methamphetamine use problems found that 21 participants, or 77.8%, had never previously sought treatment for methamphetamine use. Research Highlights Most had never sought treatment: Peart et al. interviewed 27 adults and found that 77.8% had not previously sought methamphetamine treatment before entering the parent trial.1 3 …
A 12-week randomized pilot trial in 60 Veterans with depression and psychiatric polypharmacy found that 30% had an actionable antidepressant gene-drug interaction, but immediate access to pharmacogenomic results did not clearly change prescribing or Patient Health Questionnaire-9 depression scores compared with delayed access.1 Research Highlights Actionable PGx results were common: 18 of 60 Veterans, or …
A 2026 nationwide Korean analysis found that resistance exercise was associated with lower depression and anxiety scores after propensity score matching, while aerobic exercise alone was not significantly associated with either outcome. The result favors adding weights, bands, machines, or body-weight strength work to mental-health exercise advice without assuming that lifting caused the lower symptom …
A 2026 qualitative analysis treated suicide-themed sculpture as cultural evidence, showing how public artworks can materialize psychological pain, shame, entrapment, social disconnection, and prevention debates without turning artists or viewers into diagnostic case studies.1 Research Highlights 2026 analysis used cultural methods: the researchers used iconographic, semiotic, and contextual analysis rather than clinical diagnosis or outcome …
Intranasal esketamine — FDA-approved for treatment-resistant depression in 2019 — failed cost-effectiveness benchmarks against four cheaper third-line options in a 2026 Hong Kong modeling study, with incremental cost-effectiveness ratios (ICERs) of US$134,127 to US$312,750 per quality-adjusted life-year (QALY) at a US$50,000/QALY willingness-to-pay (WTP) threshold.1 Combination antidepressant therapy was the most cost-effective strategy modeled. Research Highlights …
A 2026 study of 958 adults entering Japanese multidisciplinary pain centers found that 17.1% screened positive for ADHD, rising to 27.4% among patients whose average pain was NRS 9-10; ASD screening was 4.4% overall and did not show the same pain-intensity signal.1 Research Highlights ADHD screening was elevated in tertiary pain care: 164 of 958 …
A 2026 ALSPAC analysis tested a narrow claim behind routine genetic screening for childhood attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD): whether rare copy number variants (CNVs; deleted or duplicated DNA segments) make young-adult outcomes worse than ADHD/ASD status alone would predict. In 8,414 people with usable CNV data, ADHD and ASD predicted worse …